Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company is headquartered in Los Angeles, California and currently employs 18 full-time employees. The company went IPO on 2021-12-16. The firm is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The firm's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
Follow-Up Questions
Immix Biopharma Inc 的 CEO 是谁？
Dr. Ilya Rachman 是 Immix Biopharma Inc 的 Chairman of the Board，自 2012 加入公司。
IMMX 股票的价格表现如何？
IMMX 的当前价格为 $2.87，在上个交易日 decreased 了 0%。
Immix Biopharma Inc 的主要业务主题或行业是什么？
Immix Biopharma Inc 属于 Biotechnology 行业，该板块是 Health Care
